Chest ACCP Career Connection
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Capelli, A
Right arrow Articles by Donner, C.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Capelli, A
Right arrow Articles by Donner, C.

Chest, Vol 99, 546-550, Copyright © 1991 by American College of Chest Physicians


ARTICLES

Acid phosphatase (EC 3.1.3.2) activity in alveolar macrophages from patients with active sarcoidosis

A Capelli, M Lusuardi, S Carli and CF Donner
Clinica del Lavoro Foundation, Institute of Care and Research, Veruno, Italy.

Five main acid phosphatase (AcP) zones have been recognized and studied by polyacrylamide-gel electrophoresis. Band 5 represents the only tartrate-resistant form and is present in bone osteoclasts and in human alveolar macrophages (AMs). This study was carried out to quantify the presence of total and tartrate-resistant AcP (TrAcP) in AMs from bronchoalveolar lavage (BAL) of 11 patients with first stage sarcoidosis and in 13 nonsmokers and 16 smokers serving as control healthy subjects. The AMs from smokers showed an increase in total AcP activity (115.9 +/- 77.8 mU/10(6)); on the contrary, macrophages of patients with sarcoidosis revealed a consistent decrease in total AcP (27.8 +/- 7.0 mU/10(6)) and particularly the TrAcP subtype (14.8 +/- 3.7 mU/10(6)) in comparison with control nonsmokers (AcP = 42.2 +/- 18.9 mU/10(6) [p = NS]; TrAcP = 35.1 +/- 15.1 mU/10(6) [p less than 0.005]). The decrease in TrAcP activity was inversely correlated with the lymphocyte number (r = -0.75; p less than 0.01), lymphocyte percentage (r = -0.62; p less than 0.05), and CD4/CD8 ratio (r = -0.61; p less than 0.05). After six months of follow-up, the cytologic BAL picture returned completely to normal in five patients with full spontaneous regression of sarcoidosis; and also at the same time, normal values of TrAcP activity were restored. Since TrAcP activity can be easily detected, its possible use, along with the lymphocyte count and CD4/CD8 ratio, as a prognostic indicator of the clinical course of sarcoidosis deserves further investigation.





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1991 by the American College of Chest Physicians.